Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Mass Balance of Firazorexton (TAK-994) in Healthy Men
NCT04833049Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of firazorexton in narcolepsy, sponsored by Takeda. Primary endpoints: Percent Absolute Bioavailability (%F) for TAK-994, Percentage of Total Radioactivity (TRA) in Urine and 2 more. Started Apr 2021; status: completed.
02
Drugs
firazorexton
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT04833049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833049.